Molecular and cellular mechanisms of pentadecanoic acid
World Journal of Biological Chemistry · 05.12.2025 · 16 (4)
DOI: 10.4331/wjbc.v16.i4.111258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Biological Chemistry, online erschienen am 05.12.2025. Verfasst von Joseph Mercola. Beteiligte Einrichtung: Midwestern University, Downers Grove, IL 60515, United States. drm@mercola.com. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pentadecanoic acid (C15:0) is an odd-chain fatty acid, the β-oxidation of which yields propionyl-CoA that replenishes succinyl-CoA and tricarboxylic acid cycle flux; higher circulating levels are associated with reduced type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and mortality. Summarize the cellular and molecular mechanisms underlying these associations. A comprehensive literature search (2000-2025) identified studies of C15:0’s mechanistic actions in vitro and in vivo , and multi-omics studies focused on receptor binding, signaling cascades, gene expression, and comparative pharmacology. C15:0 is a dual partial peroxisome proliferator-activated receptor α/δ agonist. It activates AMP-activated protein kinase, suppresses mechanistic target of rapamycin, and selectively inhibits histone deacetylase 6. It augments succinate-driven complex II respiration, preserves mitochondrial membrane potential, limits reactive oxygen species, and attenuates interleukin-6 (IL-6) – triggered Janus kinase 2/signal transducer and activator of transcription 3 and nuclear factor kappa B p65 signaling, lowering monocyte chemoattractant protein-1, tumor necrosis factor-alpha, and IL-6. Across the BioMAP® human-primarycell platform – which tests 12 distinct primary human cell systems such as endothelial cells, fibroblasts, macrophages, and T-cells – C15:0 (17 µM) produced statistically significant changes in 36 mechanistically diverse biomarkers. This broad, multi-pathway modulation mirrors the phenotype produced by metformin and rapamycin, yet occurred with no detectable cytotoxicity, paralleling metformin and rapamycin with negligible cytotoxicity. C15:0 engages receptor targets that converge on enhanced lipid oxidation, cellular energetics, and inflammation resolution. Although prospective clinical outcomes are still lacking, the pleiotropic mechanism profile positions C15:0 as a potentially unique nutraceutical or adjunct therapeutic candidate. Further research is warranted to confirm its clinical impacts, optimize dosing, and clarify long-term safety as an essential fatty acid supporting metabolic and immune homeostasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Midwestern University, Downers Grove, IL 60515, United States. drm@mercola.com.
Zitieren
APA
Mercola, J. (2025). Molecular and cellular mechanisms of pentadecanoic acid. World Journal of Biological Chemistry, 16(4). https://doi.org/10.4331/wjbc.v16.i4.111258
Vancouver
Mercola J. Molecular and cellular mechanisms of pentadecanoic acid. World Journal of Biological Chemistry. 2025;16(4). doi:10.4331/wjbc.v16.i4.111258
BibTeX
@article{Mercola2025,
author = {Mercola, Joseph},
title = {Molecular and cellular mechanisms of pentadecanoic acid},
journal = {World Journal of Biological Chemistry},
year = {2025},
volume = {16},
number = {4},
doi = {10.4331/wjbc.v16.i4.111258}
}
EUVIMED